Dr. Holmes’s research laboratory focuses on the role of platelets in tumor angiogenesis and metastasis and the inhibition of cancer progression using platelet antagonist therapy. Studies conducted in our laboratory suggest protein release from platelets can be selectively regulated to influence cancer progression. Current studies focus on the influence of key platelet activation pathways and selective activation antagonists on angiogenic protein release from platelets and the processes of angiogenesis and metastasis using cellular models. Clinical studies are currently accruing patients to determine the influence of aspirin therapy and plavix therapy on platelets in women with breast cancer.
In addition to platelet based laboratory and clinical studies, Dr. Holmes also has an active clinical and research interest in thrombosis and hemostasis. She is the PI for a recently completed single center, randomized, blinded study designed to determine the impact of lymphedema therapy on post-thrombotic syndrome is also actively involved in thrombosis and malignancy program.
1997 M.D., University of Virginia School of Medicine
1993 Ph.D., University of Virginia Graduate School of Arts and Sciences, Department of Chemistry
1988 B.S., James Madison University, Department of Chemistry, Magna Cum Laude, Honors Scholar2001-2004 Fellow, Hematology & Oncology, University of Vermont and Fletcher Allen Health Care
2002 Postdoctoral Research Fellow, National Institutes of Health, University of Vermont, Hemostasis and Thrombosis Program for Academic Trainees
2000-2001 Chief Resident, Department of Internal Medicine, University of Vermont
1998-2000 Resident, Internal Medicine, University of Vermont-Fletcher Allen Health Care
1997-1998 Intern, Internal Medicine, University of Vermont-Fletcher Allen Health Care
2000 Certified, Internal Medicine, American Board of Internal Medicine
2002 Licensure, State of Vermont, Board of Medical Practice
2004 Certified, Hematology, American Board of Internal Medicine
2004 Certified, Medical Oncology, American Board of Internal Medicine
2001 American Society of Hematology
2001 American Society of Clinical Oncology
2002 Alliance for Clinical Trials in Oncology (Alliance)
1997 American College of Physicians
Bambace NM, Holmes CE. The Platelet Contribution to Cancer Progression. J Thromb Haemost. 2010; 9: 237-249.
Bambace NM, Levis JE, Holmes CE. The Effect of P2Y-Mediated Activation on VEGF and Endostatin Release from Platelets. Platelets 2010; 21: 85-93.Holmes CE, Levis J, Ornstein DL. Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis, Clin Exp Metastasis 2009, epub, 10.1007/s10585-009-9264-9.
Holmes, C.E., Huang, J.C., Cartelli, C., Rimmer, J. & Cushman, M.C. “The Frequency of Thrombocytopenia and Clinical Evaluation of Heparin-Induced Thrombocytopenia in Patients Receiving Continuous Renal Replacement Therapy”, 2007, manuscript under review by co-authors.Snoep JD, Gaussem P, Eikenboom JCJ, Emmerich, J, Zwaginga JJ, Holmes CE, Vos HL, de Groot PG, Rosendaal FR, van der Bom JG. The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: results from the SMILE-platelets project. J Thromb Haemostasis 2010; 8: 2377-2384.
For a complete list of Chris Holmes' publications, please visit PubMed.